North American Spine Society:
Newly released vertebroplasty randomized controlled trials: a tale of two trials
To access this article, please choose from the options below
FDA device/drug status: not applicable
Author disclosures: CMB (royalties, Life Spine [Level B]; consulting, Depuy Spine [Level B], Medtronic Sofamor Danek [Level B]; speaking/teaching arrangements, Depuy Spine [Level C], Stryker Spine [Level B]; board of directors, North American Spine Society; other office, Applied Spine [Level B, Adverse Events Panel]; research support, Archus Orthopedics [Level B], Synthes Spine [Level D]; grants, Stryker Spine [Level D]; fellowship support, Depuy Spine [Level E]); MH (royalties, Relievant Medsystems [Level C]; stock ownership, Relievant Medsystems [Level D]; consulting, Relievant Medsystems [Level D, 2008; none, 2009]; board of directors, North American Spine Society; research support, investigator salary, Department of Defense [Level E]; grants, Department of Defense [Level I, not directly related to the spine]); CM (board of directors, North American Spine Society; relationships outside the 1-year requirement, DePuy [Level A], Synthes [Level A], St. Francis Medical [Level A]; other, NASS Board, Coding Committee, Performance Measure Committee, Advocacy Council Chair, Annual Meeting, NASS RUC Rep); DR (board of directors, North American Spine Society; relationships outside the 1-year requirement, Medtronic [consultant 2003–2006, minimal-less than Level B over entire duration]); WCW (consulting, Stryker [Level C]; board of directors, North American Spine Society; scientific advisory board, Intrinsic Therapeutics [nonfinancial, stock options (no current value)]; others, Blackstone Medical Inc. [financial, Clinical Events Committee for clinical trial]).
PII: S1529-9430(09)00984-X
doi:10.1016/j.spinee.2009.09.007
© 2010 Elsevier Inc. All rights reserved.
